Strong anti-tumor effects detected in Alpha1H treated patients, for a combination of clinical and molecular endpoints
Hamlet BioPharma, the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, announces the results for the investigational drug Alpha1H, in patients with bladder cancer. The analysis of the combined data set from two clinical study parts has now been completed and submitted for publication. Treatment resulted in a significant reduction in tumor size in 82% of tumors treated with the higher and 45% of tumors treated with the lower dose of Alpha1H. Hamlet BioPharma is now proceeding with the third part of the clinical trial to optimize the design